Literature DB >> 17357488

Relationship between PTEN and VEGF expression and clinicopathological characteristics in HCC.

Denghai Mi1, Jilin Yi, Enyu Liu, Xingrui Li.   

Abstract

To investigate the expressions and significance of the tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten protein (PTEN) and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC), and to analyze the relationship between their expressions and the tumor's invasion and their peri-carcinomatous tissues, the correlation of their expressions with the tumor's clinicopathological characteristics and invasion potential were studied. Our study showed that the expression level of PTEN in HCC was remarkably lower than that in peri-carcinomatous liver tissues, while the expressions of both VEGF and MVD were higher than that in peri-carcinomatous liver tissues. Correlation analysis revealed that the expression of PTEN was negatively related to the progression of the pathological differentiation and invasion of tumor, whereas the expressions of VEGF and MVD were positively related. Moreover, there was a negative relationship between the expression of PTEN and the expressions of VEGF and MVD, and a positive one between VEGF and MVD. The expressions of PTEN and VEGF may reveal the degree of differentiation and the invasive potential of HCC tissues. The mechanism by which the lack of PTEN expression probably induces abnormal hyperexpression of VEGF may play an important role in the invasion and metastasis of HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17357488     DOI: 10.1007/s11596-006-0614-4

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  13 in total

1.  Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.

Authors:  V Zolota; A Gerokosta; M Melachrinou; A Kominea; C Aletra; C D Scopa
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

Review 2.  Angiogenesis.

Authors:  J Folkman; Y Shing
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

3.  Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN.

Authors:  M Tamura; J Gu; K Matsumoto; S Aota; R Parsons; K M Yamada
Journal:  Science       Date:  1998-06-05       Impact factor: 47.728

Review 4.  New perspectives in clinical oncology from angiogenesis research.

Authors:  J Folkman
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

5.  Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma.

Authors:  O N el-Assal; A Yamanoi; Y Soda; M Yamaguchi; L Yu; N Nagasue
Journal:  Surgery       Date:  1997-09       Impact factor: 3.982

6.  A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.

Authors: 
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

7.  Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.

Authors:  H Miura; T Miyazaki; M Kuroda; T Oka; R Machinami; T Kodama; M Shibuya; M Makuuchi; Y Yazaki; S Ohnishi
Journal:  J Hepatol       Date:  1997-11       Impact factor: 25.083

8.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

9.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

Authors:  D R Senger; S J Galli; A M Dvorak; C A Perruzzi; V S Harvey; H F Dvorak
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

10.  Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity.

Authors:  Hiroyuki Hisai; Junji Kato; Masayoshi Kobune; Tsuzuku Murakami; Koji Miyanishi; Minoru Takahashi; Naohito Yoshizaki; Rishu Takimoto; Takeshi Terui; Yoshiro Niitsu
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  3 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

2.  Fibrosis in Chronic Hepatitis C: Correlation between Immunohistochemically-Assessed Virus Load with Steatosis and Cellular Iron Content.

Authors:  Maha Akl; Ali El Hindawi; Maha Mosaad; Ahmed Montasser; Ahmed El Ray; Heba Khalil; Amgad Anas; Raffat Atta; Valerie Paradis; Ahmed Abdel Hadi; Olfat Hammam
Journal:  Open Access Maced J Med Sci       Date:  2016-11-15

Review 3.  Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.

Authors:  Xiao-Xiao Ding; Qing-Ge Zhu; Shi-Ming Zhang; Lei Guan; Ting Li; Lei Zhang; Shi-Yang Wang; Wan-Li Ren; Xue-Mei Chen; Jing Zhao; Song Lin; Zhi-Zhen Liu; Yan-Xia Bai; Bing He; Hu-Qin Zhang
Journal:  Oncotarget       Date:  2017-06-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.